Ochre Bio CEO Jack O'Meara discusses his company's focus on liver diseases and its recent Boehringer Ingelheim partnership

blonca9
May 6, 2024
1 min read

Jack O'Meara describes Ochre's unique preclinical testing strategy as it develops siRNA drugs for liver diseases, and he touches on a high profile partnership the company signed in recent weeks.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

Ochre Bio CEO Jack O'Meara discusses his company's focus on liver diseases and its recent Boehringer Ingelheim partnership

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight